<p>～资金支持 PF614 的第三阶段临床开发，并持续创新耐滥用和耐过量的镇痛药～</p>
<p>加利福尼亚州圣地亚哥 / ACCESS Newswire /2025 年 11 月 17 日/ Ensysce Biosciences, Inc.（&#34;Ensysce&#34;或&#34;公司&#34;），致力于开发具有内置滥用和过量保护的新型重度疼痛解决方案，今天宣布完成 400 万美元的可转换优先股融资，未来 24 个月内可能获得额外 1600 万美元的资金。</p>
<p>这笔资金将加速 PF614 的第三阶段临床项目，这是 Ensysce 的旗舰镇痛药候选药物，同时支持一般企业计划。初始的 400 万美元融资包括每股 2.50 美元的固定转换价格，转换时的替代价格基于转换前的普通股平均价格。该融资在每次融资中包括 50% 的认股权证覆盖，认股权证可在固定转换价格下行使，行使期为五年，受调整限制。</p>
<p><strong>关键亮点：</strong></p>
<ul>
<li>现已关闭 400 万美元，额外 1600 万美元可用：提供资金灵活性以推进关键项目。</li>
<li>第三阶段加速：PF614 临床试验将在 18-24 个月内向市场准备。</li>
<li>投资者信心：当前支持者继续支持 Ensysce 的使命驱动创新。</li>
</ul>
<p>Ensysce Biosciences 首席执行官 Kirkpatrick 博士表示：&#34;这笔融资展示了投资者对 Ensysce 愿景的强烈信心：安全、有效的镇痛药重新定义疼痛管理。PF614 预计将在未来 18 个月内完成第三阶段，并获得联邦资助支持我们的 MPAR 项目，我们正朝着为急需患者提供变革性治疗的目标迈进。&#34;</p>
<p><strong>关于 Ensysce Biosciences</strong></p>
<p>Ensysce Biosciences 是一家临床阶段公司，旨在通过引入一种新型高度新颖的阿片类药物来颠覆镇痛药市场，以治疗重度疼痛。公司利用其胰蛋白酶激活的滥用保护（TAAPTM）和多药滥用抵抗（MPAR®）平台，开发独特的防篡改疼痛治疗选项，最大限度地降低药物滥用和过量的风险。Ensysce 的产品预计将为重度疼痛患者提供更安全的治疗选择，并帮助防止因药物滥用导致的死亡。Ensysce 的产品线得到了强大的全球知识产权组合的支持，为面临疼痛管理挑战的患者和提供者带来了希望。了解更多信息，请访问 www.ensysce.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿中包含的声明如果不是纯粹的历史性声明，可能被视为 1995 年《私人证券诉讼改革法案》和其他联邦证券法下的安全港条款的前瞻性声明。在不限制前述内容的情况下，使用&#34;可能&#34;、&#34;打算&#34;、&#34;可以&#34;、&#34;可能&#34;、&#34;将&#34;、&#34;期望&#34;、&#34;计划&#34;、&#34;可能&#34;、&#34;相信&#34;及其他类似表达的词语旨在识别前瞻性声明。讨论的产品候选药物正在进行临床试验，尚未获得批准，不能保证临床项目将成功证明安全性和/或有效性，Ensysce 不会在临床开发中遇到问题或延误，或任何产品候选药物将获得监管批准或成功商业化。所有前瞻性声明均基于 Ensysce 管理层的估计和假设，尽管 Ensysce 认为这些估计和假设是合理的，但本质上是不确定的。所有前瞻性声明均受到可能导致实际结果与 Ensysce 预期结果显著不同的风险和不确定性的影响。此外，Ensysce 的业务还面临其他风险和不确定性，包括但不限于，前临床研究和临床试验的启动和进行；前临床研究和临床试验的数据时间和可用性；对监管提交和批准的预期；与 Ensysce 的产品候选药物相关的潜在安全问题或有效性；产品候选药物的可用性或商业潜力；Ensysce 为其持续运营提供资金的能力，包括其计划的临床试验；我们融资中股票发行的稀释效应；以及 Ensysce 及其合作伙伴在其许可、合作和制造安排下的履约能力。这些声明还受到 Ensysce 最近在 Form 10-Q 上的季度报告和在 Form 8-K 上的当前报告中描述的若干重大风险和不确定性的影响，这些报告可在 SEC 网站 www.sec.gov 上免费获取。任何前瞻性声明仅在作出之日有效。Ensysce 没有义务公开更新或修订任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，除非适用法律要求。</p>
<p><strong>Ensysce Biosciences 公司联系方式：</strong></p>
<p>Lynn Kirkpatrick, Ph.D.</p>
<p>首席执行官</p>
<p>(858) 263-4196</p>
<p><strong>Ensysce Biosciences 投资者关系联系方式：</strong></p>
<p>Shannon Devine</p>
<p>MZ North America</p>
<p>电话：203-741-8811</p>
<p>ENSC@mzgroup.us</p>
<p><strong>来源：</strong> Ensysce Biosciences Inc.</p>
<p>查看 ACCESS Newswire 上的原始新闻稿</p>

ENSC

<p>Ensysce Biosciences 已获得 400 万美元的可转换优先股融资，并有可能在 24 个月内获得额外的 1600 万美元。这笔资金将加速 PF614 的三期临床开发，这是一种新型镇痛药，并支持公司的各项计划。这项融资反映了投资者对 Ensysce 开发抗滥用和抗过量疼痛治疗的使命的强烈信心。该公司旨在在 18-24 个月内完成三期试验，向提供更安全的疼痛管理解决方案迈进</p>

<p>~Funding supports Phase 3 clinical development of PF614 and continued innovation in abuse- and overdose-resistant analgesics~</p>
<div class="lb-trans"><p>～资金支持 PF614 的第三阶段临床开发，并持续创新耐滥用和耐过量的镇痛药～</p>
</div><p>SAN DIEGO, CA / ACCESS Newswire / November 17, 2025 / Ensysce Biosciences, Inc. (&#34;Ensysce&#34; or the &#34;Company&#34;), pioneering novel solutions for severe pain with built-in abuse and overdose protection, today announced the closing of a $4 million convertible preferred stock financing, with upside to potentially $16 million of additional funding available through future tranches over the next 24 months.</p>
<div class="lb-trans"><p>加利福尼亚州圣地亚哥 / ACCESS Newswire /2025 年 11 月 17 日/ Ensysce Biosciences, Inc.（&#34;Ensysce&#34;或&#34;公司&#34;），致力于开发具有内置滥用和过量保护的新型重度疼痛解决方案，今天宣布完成 400 万美元的可转换优先股融资，未来 24 个月内可能获得额外 1600 万美元的资金。</p>
</div><p>The capital will accelerate the Phase 3 clinical program for PF614, Ensysce's flagship analgesic candidate, while supporting general corporate initiatives. The initial $4 million tranche includes a fixed conversion price of $2.50 per share, with an alternate conversion price based upon average common stock prices prior to conversion. The financing includes 50% warrant coverage on each takedown, exercisable at the fixed conversion price for five years, subject to adjustment.</p>
<div class="lb-trans"><p>这笔资金将加速 PF614 的第三阶段临床项目，这是 Ensysce 的旗舰镇痛药候选药物，同时支持一般企业计划。初始的 400 万美元融资包括每股 2.50 美元的固定转换价格，转换时的替代价格基于转换前的普通股平均价格。该融资在每次融资中包括 50% 的认股权证覆盖，认股权证可在固定转换价格下行使，行使期为五年，受调整限制。</p>
</div><p><strong>Key Highlights:</strong></p>
<div class="lb-trans"><p><strong>关键亮点：</strong></p>
</div><ul>
<li>$4 Million Closed Now, $16 Million Available: Providing funding flexibility to advance critical programs.</li>
<li>Phase 3 Acceleration: PF614 clinical trials moving toward market readiness within 18-24 months.</li>
<li>Investor Confidence: Current backers continue to support Ensysce's mission-driven innovation.</li>
</ul>
<div class="lb-trans"><ul>
<li>现已关闭 400 万美元，额外 1600 万美元可用：提供资金灵活性以推进关键项目。</li>
<li>第三阶段加速：PF614 临床试验将在 18-24 个月内向市场准备。</li>
<li>投资者信心：当前支持者继续支持 Ensysce 的使命驱动创新。</li>
</ul>
</div><p>Dr. Kirkpatrick, CEO of Ensysce Biosciences, stated, &#34;This financing demonstrates strong investor confidence in Ensysce's vision: safe, effective analgesics that re-invent pain management. With PF614 on track for Phase 3 completion in the next 18 months and federal grant support for our MPAR program, we are moving closer to delivering transformative treatments for patients in urgent need.&#34;</p>
<div class="lb-trans"><p>Ensysce Biosciences 首席执行官 Kirkpatrick 博士表示：&#34;这笔融资展示了投资者对 Ensysce 愿景的强烈信心：安全、有效的镇痛药重新定义疼痛管理。PF614 预计将在未来 18 个月内完成第三阶段，并获得联邦资助支持我们的 MPAR 项目，我们正朝着为急需患者提供变革性治疗的目标迈进。&#34;</p>
</div><p><strong>About Ensysce Biosciences</strong></p>
<div class="lb-trans"><p><strong>关于 Ensysce Biosciences</strong></p>
</div><p>Ensysce Biosciences is a clinical stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. Ensysce's pipeline is backed by a robust global intellectual property portfolio, offering hope to patients and providers confronting the challenges of pain management. Learn more at www.ensysce.com.</p>
<div class="lb-trans"><p>Ensysce Biosciences 是一家临床阶段公司，旨在通过引入一种新型高度新颖的阿片类药物来颠覆镇痛药市场，以治疗重度疼痛。公司利用其胰蛋白酶激活的滥用保护（TAAPTM）和多药滥用抵抗（MPAR®）平台，开发独特的防篡改疼痛治疗选项，最大限度地降低药物滥用和过量的风险。Ensysce 的产品预计将为重度疼痛患者提供更安全的治疗选择，并帮助防止因药物滥用导致的死亡。Ensysce 的产品线得到了强大的全球知识产权组合的支持，为面临疼痛管理挑战的患者和提供者带来了希望。了解更多信息，请访问 www.ensysce.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as &#34;may,&#34; &#34;intends,&#34; &#34;can,&#34; &#34;might,&#34; &#34;will,&#34; &#34;expect,&#34; &#34;plan,&#34; &#34;possible,&#34; &#34;believe&#34; and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, available free of charge at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.</p>
<div class="lb-trans"><p>本新闻稿中包含的声明如果不是纯粹的历史性声明，可能被视为 1995 年《私人证券诉讼改革法案》和其他联邦证券法下的安全港条款的前瞻性声明。在不限制前述内容的情况下，使用&#34;可能&#34;、&#34;打算&#34;、&#34;可以&#34;、&#34;可能&#34;、&#34;将&#34;、&#34;期望&#34;、&#34;计划&#34;、&#34;可能&#34;、&#34;相信&#34;及其他类似表达的词语旨在识别前瞻性声明。讨论的产品候选药物正在进行临床试验，尚未获得批准，不能保证临床项目将成功证明安全性和/或有效性，Ensysce 不会在临床开发中遇到问题或延误，或任何产品候选药物将获得监管批准或成功商业化。所有前瞻性声明均基于 Ensysce 管理层的估计和假设，尽管 Ensysce 认为这些估计和假设是合理的，但本质上是不确定的。所有前瞻性声明均受到可能导致实际结果与 Ensysce 预期结果显著不同的风险和不确定性的影响。此外，Ensysce 的业务还面临其他风险和不确定性，包括但不限于，前临床研究和临床试验的启动和进行；前临床研究和临床试验的数据时间和可用性；对监管提交和批准的预期；与 Ensysce 的产品候选药物相关的潜在安全问题或有效性；产品候选药物的可用性或商业潜力；Ensysce 为其持续运营提供资金的能力，包括其计划的临床试验；我们融资中股票发行的稀释效应；以及 Ensysce 及其合作伙伴在其许可、合作和制造安排下的履约能力。这些声明还受到 Ensysce 最近在 Form 10-Q 上的季度报告和在 Form 8-K 上的当前报告中描述的若干重大风险和不确定性的影响，这些报告可在 SEC 网站 www.sec.gov 上免费获取。任何前瞻性声明仅在作出之日有效。Ensysce 没有义务公开更新或修订任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，除非适用法律要求。</p>
</div><p><strong>Ensysce Biosciences Company Contact:</strong></p>
<div class="lb-trans"><p><strong>Ensysce Biosciences 公司联系方式：</strong></p>
</div><p>Lynn Kirkpatrick, Ph.D.</p>
<div class="lb-trans"><p>Lynn Kirkpatrick, Ph.D.</p>
</div><p>Chief Executive Officer</p>
<div class="lb-trans"><p>首席执行官</p>
</div><p>(858) 263-4196</p>
<div class="lb-trans"><p>(858) 263-4196</p>
</div><p><strong>Ensysce Biosciences Investor Relations Contact:</strong></p>
<div class="lb-trans"><p><strong>Ensysce Biosciences 投资者关系联系方式：</strong></p>
</div><p>Shannon Devine</p>
<div class="lb-trans"><p>Shannon Devine</p>
</div><p>MZ North America</p>
<div class="lb-trans"><p>MZ North America</p>
</div><p>Main: 203-741-8811</p>
<div class="lb-trans"><p>电话：203-741-8811</p>
</div><p>ENSC@mzgroup.us</p>
<div class="lb-trans"><p>ENSC@mzgroup.us</p>
</div><p><strong>SOURCE:</strong> Ensysce Biosciences Inc.</p>
<div class="lb-trans"><p><strong>来源：</strong> Ensysce Biosciences Inc.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新闻稿</p>
</div>

Ensysce Biosciences 获得 400 万美元融资，总融资额最高可达 2000 万美元，用于推进突破性疼痛项目